GAMMA Investing LLC Boosts Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

GAMMA Investing LLC boosted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 43,744.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 105,226 shares of the company's stock after purchasing an additional 104,986 shares during the period. GAMMA Investing LLC owned about 0.31% of TransMedics Group worth $7,080,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of TMDX. Atlas Capital Advisors Inc. purchased a new position in TransMedics Group in the fourth quarter worth $31,000. AlphaQuest LLC purchased a new position in TransMedics Group in the fourth quarter worth $52,000. Arcadia Investment Management Corp MI purchased a new position in TransMedics Group in the fourth quarter worth $72,000. Rakuten Securities Inc. boosted its position in TransMedics Group by 68.3% in the fourth quarter. Rakuten Securities Inc. now owns 1,355 shares of the company's stock worth $84,000 after purchasing an additional 550 shares during the last quarter. Finally, Venturi Wealth Management LLC boosted its position in TransMedics Group by 58.0% in the fourth quarter. Venturi Wealth Management LLC now owns 1,373 shares of the company's stock worth $86,000 after purchasing an additional 504 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 6,000 shares of the business's stock in a transaction on Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now directly owns 732 shares in the company, valued at approximately $84,641.16. The trade was a 89.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David Weill sold 732 shares of the company's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the transaction, the director now owns 12,134 shares in the company, valued at $1,503,159.92. This represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,732 shares of company stock worth $1,416,710. 7.00% of the stock is owned by company insiders.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $139.05 on Monday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The firm has a market cap of $4.70 billion, a price-to-earnings ratio of 147.93 and a beta of 2.10. The business's fifty day moving average is $101.54 and its 200 day moving average is $80.29.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. During the same period in the previous year, the company posted $0.35 EPS. The firm's revenue for the quarter was up 48.2% compared to the same quarter last year. Research analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on TMDX. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 3rd. Canaccord Genuity Group reaffirmed a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Finally, Oppenheimer upped their price target on TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $125.11.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.